about
Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins--identification of additional interacting regionsSuppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domainsTrim24 targets endogenous p53 for degradationMaintaining Genome Stability in Defiance of Mitotic DNA DamageDrugging the undruggables: exploring the ubiquitin system for drug developmentRegulation of Mutant p53 Protein ExpressionTargeting Oncogenic Mutant p53 for Cancer TherapyThe rebel angel: mutant p53 as the driving oncogene in breast cancer.MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activityAge-related retinal degeneration (arrd2) in a novel mouse model due to a nonsense mutation in the Mdm1 geneFunctional interplay between MDM2, p63/p73 and mutant p53Ubiquitination of human AP-endonuclease 1 (APE1) enhanced by T233E substitution and by CDK5.Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene TherapyMutant p53 gain-of-function in cancer.A novel p53 phosphorylation site within the MDM2 ubiquitination signal: I. phosphorylation at SER269 in vivo is linked to inactivation of p53 function.Degradation of mutant p53H175 protein by Zn(II) through autophagy.Ataxin-3 expression correlates with the clinicopathologic features of gastric cancerMutant TP53 posttranslational modifications: challenges and opportunities.Haploinsufficient tumor suppressor genes.Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.Mdm2 facilitates the association of p53 with the proteasome.The role of mutant p53 in human cancer.Limiting the power of p53 through the ubiquitin proteasome pathway.A novel mechanism of crosstalk between the p53 and NFκB pathways: MDM2 binds and inhibits p65RelA.Intact MDM2 E3 ligase activity is required for the cytosolic localization and function of β-arrestin2Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cellsTid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer.SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.Long Noncoding RNA MEG3 Interacts with p53 Protein and Regulates Partial p53 Target Genes in Hepatoma CellsIt Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.Modulation of cancer traits by tumor suppressor microRNAs.Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?Protein quality control and degradation in cardiomyocytes.Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.
P2860
Q24299141-2BD297EF-B34A-4BD5-9930-BF331A049446Q24309310-3BA51D28-4F85-4874-908F-11AD5421840DQ24315623-08A993CC-D70D-4EFC-9267-DE45334C9B00Q24339423-59F95023-A8CF-4903-B4F5-5182413A43DAQ26738970-03C6D9F5-2CFA-4A35-A6B8-4ADA7486071CQ26752823-A02CE7DE-A44A-41F3-9417-CD6C1DF9DF20Q26770579-899E8187-AB39-4D16-9400-23E8E0080B5DQ26770856-9FC6DBD0-8C40-4540-A99B-64FDED693F03Q27686765-8B518E1B-35CC-447B-9D0A-6624236F8569Q28118946-A628C1FD-B839-4560-B2D0-24656A5EB562Q28506396-0F2B1E60-3F67-462B-ACB1-48243E3F223CQ28910323-C9C6FE9C-ECF5-46AA-B9B8-7043E2F78759Q30430399-75DF3DCB-B8AA-4E91-92FB-FC0FC51A76D0Q33633277-110C2125-4DBB-422A-A889-7EE76B64628EQ33687048-D1587031-FD16-4568-A80A-8C95A1EF705DQ33695618-F13734D0-A223-4F9C-8E12-C5B3F24821C4Q33709136-ECAD9457-93B3-4303-A8F9-22BD9C592788Q33756282-DEBA77CA-F783-47AB-9256-4A82B18476F3Q33818479-FD02BC47-AEC8-4F28-A43F-E5740AE77814Q33864922-77236A76-E067-4C06-A11F-F1EB93136771Q33865095-F1F4FA3F-8EA4-426C-84B1-A696EFD0F0DFQ33874242-50E41B83-643A-4EA0-BA51-CBAA0FDF64B8Q33933283-B3BFEAD9-E805-471C-8FA9-4A9E6F4D8D03Q34153014-B4497C53-3A65-4FCD-957D-0CD5DD83A051Q34342940-8E95FAF3-DD8E-45CD-A030-42B0A52424CFQ34356362-593A950A-8B35-4BC3-87EB-8C52EF0A4A40Q34888305-FE8F4FF7-B8ED-4486-B392-BE8354F955F6Q34978872-AEC85D46-B890-4688-B463-6047A610F71BQ34989395-E67CFD9F-91E6-459A-A56C-B5B18AD0DA1CQ35014396-812E70A5-E51E-497D-97EB-C688D11B3EADQ35207366-3C08B909-9A9D-400F-B429-5781D7E5103EQ36032139-4885A230-6885-4DE1-9B3A-72736E0D061BQ36133137-B5982EC6-DE09-482B-A337-F17100850E8AQ36387588-CC83819C-3D4D-4D06-B6C5-0A8C1499D978Q36544120-6BC8D42F-AC9B-470A-85F7-1A7FE5FCB8D8Q36546609-AA09AD1C-3A74-42E1-A4AE-BE3643368CFDQ36590130-A4062DA6-E110-4C6E-AE29-D40D49A473F7Q36823657-027458A6-5666-4828-B4B2-D2F1379E3A0EQ36952213-B25D1134-767B-460F-B9ED-9AF846710C74Q36998944-9EDD3D0C-DEB6-4592-9F47-EC5F8EEE8DDA
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Ubiquitination and degradation of mutant p53.
@en
type
label
Ubiquitination and degradation of mutant p53.
@en
prefLabel
Ubiquitination and degradation of mutant p53.
@en
P2860
P356
P1476
Ubiquitination and degradation of mutant p53.
@en
P2093
Karen H Vousden
Natalia Lukashchuk
P2860
P304
P356
10.1128/MCB.00050-07
P407
P577
2007-10-01T00:00:00Z